ATE521639T1 - Monoklonale antikörper und immundetektionsprüfung spezifisch für das chemotaktische epitop des urokinase-plasminogenaktivator-rezeptors - Google Patents

Monoklonale antikörper und immundetektionsprüfung spezifisch für das chemotaktische epitop des urokinase-plasminogenaktivator-rezeptors

Info

Publication number
ATE521639T1
ATE521639T1 AT06723356T AT06723356T ATE521639T1 AT E521639 T1 ATE521639 T1 AT E521639T1 AT 06723356 T AT06723356 T AT 06723356T AT 06723356 T AT06723356 T AT 06723356T AT E521639 T1 ATE521639 T1 AT E521639T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
immunodetection
plasminogen activator
urokinase plasminogen
activator receptor
Prior art date
Application number
AT06723356T
Other languages
English (en)
Inventor
Massimo Resnati
Francesco Blasi
Nikolai Sidenius
Isabella Pallavicini
Original Assignee
Wilex Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex Ag filed Critical Wilex Ag
Application granted granted Critical
Publication of ATE521639T1 publication Critical patent/ATE521639T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT06723356T 2005-03-11 2006-03-10 Monoklonale antikörper und immundetektionsprüfung spezifisch für das chemotaktische epitop des urokinase-plasminogenaktivator-rezeptors ATE521639T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05005374 2005-03-11
PCT/EP2006/002243 WO2006094828A2 (en) 2005-03-11 2006-03-10 Monoclonal antibodies and immunodetection assay specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor

Publications (1)

Publication Number Publication Date
ATE521639T1 true ATE521639T1 (de) 2011-09-15

Family

ID=36754533

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06723356T ATE521639T1 (de) 2005-03-11 2006-03-10 Monoklonale antikörper und immundetektionsprüfung spezifisch für das chemotaktische epitop des urokinase-plasminogenaktivator-rezeptors

Country Status (4)

Country Link
US (1) US7951589B2 (de)
EP (1) EP1856155B1 (de)
AT (1) ATE521639T1 (de)
WO (1) WO2006094828A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
CN101798349B (zh) * 2009-12-09 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 一种抗uPAR人源化抗体及其编码基因
CN101798348B (zh) * 2009-12-09 2012-07-11 中国人民解放军军事医学科学院生物工程研究所 一种抗uPAR人源化抗体及其应用
JP2014529581A (ja) 2011-08-05 2014-11-13 イフォム・フォンダツィオーネ・インスティトゥオ・フィルチ・ディ・オンコロジア・モレコラーレ 構成的に活性なｕＰＡＲバリアントならびに阻害抗体の生成および単離へのそれの使用
CA2919687A1 (en) * 2013-08-01 2015-02-05 The General Hospital Corporation Non-glycosylated supar biomarkers and uses thereof
JP6690313B2 (ja) * 2016-03-10 2020-04-28 株式会社リコー 情報処理システムおよび情報処理方法
JP2025510548A (ja) * 2022-03-02 2025-04-15 ウォルデン バイオサイエンシズ，インコーポレイティド 新規の可溶性ウロキナーゼ型プラスミノーゲン活性化因子受容体（ｓｕＰＡＲ）結合性分子及びその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60219888T2 (de) 2001-01-25 2008-01-17 Fondazione Centro San Raffaele Del Monte Tabor Antikörper zur modulierung der upa/upar interaktion und deren verwendungen

Also Published As

Publication number Publication date
US20090202550A1 (en) 2009-08-13
EP1856155B1 (de) 2011-08-24
WO2006094828A2 (en) 2006-09-14
WO2006094828A3 (en) 2006-11-23
EP1856155A2 (de) 2007-11-21
US7951589B2 (en) 2011-05-31

Similar Documents

Publication Publication Date Title
ATE463512T1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
ATE549358T1 (de) Neuer anti-plgf-antikörper
EP2117571A4 (de) Plasminogen-aktivator-rezeptor-epitop vom urokinase-typ, daraus gewonnene monoklonale antikörper und anwendungsverfahren
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
EA201100231A1 (ru) Диагностический анализ на основе антител
SI1557462T1 (sl) Celice monocitnega izvora, ki inducirajo sprejemljivost transplantata, kot tudi njihova priprava in uporaba
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
NO20073981L (no) Criptobindende molekyler
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
CY1112912T1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BR112012007523A2 (pt) moléculas de anticorpo anti-gcc e composições e métodos relacionados
PH12012500551A1 (en) Monoclonal antibodies
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
DK1641828T3 (da) Anti-HGF-R-antistoffer og deres anvendelse
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
ATE521639T1 (de) Monoklonale antikörper und immundetektionsprüfung spezifisch für das chemotaktische epitop des urokinase-plasminogenaktivator-rezeptors
DE602006007967D1 (de) Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
DE602006018424D1 (de) Peptide zum nachweis von ehrlichia ewingii antikörper
GB0611708D0 (en) Novel antibodies against prion protein and uses thereof
MXPA06001287A (es) Identificacion y caracterizacion de anticuerpos anti-ed-b-fibronectina bloqueantes de la funcion.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties